This article is more than 5 years old. Information may no longer be current.
Growth to begin in 2016 in glaucoma treatment market
Click Here to Manage Email Alerts
The market for glaucoma pharmaceuticals is predicted to remain flat until 2016, when growth will begin as a result of the introduction of new products.
Research and consulting firm GlobalData announced in a press release that the market will rise in value from $2.4 billion in 2013 to about $3 billion by 2023 across the seven major markets, which include the U.S., France, Germany, Italy, Spain, the U.K. and Japan.
GlobalData’s report stated that the introduction of first-in-class drugs and additional fixed-dose combination products will drive the growth.
U.S. sales are expected to increase from $1.7 billion in 2013 to $2.2 billion by 2023, GlobalData stated, with the country’s overall market share rising slightly from 70.7% to 71.6% during this period.
Catherine Daly, PhD, GlobalData’s senior analyst covering neurology and ophthalmology, stated in the release: “This increase is mainly attributed to the expected introduction of several new products between 2013 and 2023 and the overall increase in glaucoma prevalence that is mostly due to an aging society in the U.S.
“However, Allergan will lose patent protection for its fixed-dose combination drug Combigan (brimonidine tartrate 0.2% and timolol maleate 0.5%) in 2022, allowing generic brimonidine and timolol fixed-dose combination products to enter the arena,” she continued. “This will negatively impact the U.S. market value and slow the overall growth rate in the last 2 years of the forecast period.”